Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Edgewise Therapeutics, Inc. (EWTX) had Normalized Pre-Tax Income of $-167.79M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-167.79M |
|
-- |
|
-- |
|
$191.41M |
|
$-191.41M |
|
$23.61M |
|
$-167.79M |
|
|
Normalized Pre-Tax Income |
$-167.79M |
$-167.79M |
|
$-167.79M |
|
$-167.79M |
|
$-167.79M |
|
$-191.41M |
|
$-196.81M |
|
102.93M |
|
102.93M |
|
$-1.63 |
|
$-1.63 |
|
| Balance Sheet Financials | |
$543.38M |
|
$7.83M |
|
$9.22M |
|
$552.60M |
|
$27.37M |
|
-- |
|
$2.98M |
|
$30.35M |
|
$522.26M |
|
$522.26M |
|
$522.26M |
|
106.25M |
|
| Cash Flow Statement Financials | |
$-143.82M |
|
$-32.79M |
|
$196.09M |
|
$41.67M |
|
$61.15M |
|
$19.48M |
|
$34.75M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
19.85 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-144.07M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-32.13% |
|
-32.13% |
|
-30.36% |
|
-32.13% |
|
$4.92 |
|
$-1.40 |
|
$-1.40 |
|